1 |
Anti-von willebrand factor nanobody, caplacizumab |
Caplacizumab |
[1] D11160 D11160 💬 |
VWF [1] VWF 💬 |
Complement and coagulation cascades [8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation |
064 [1] 64 💬 |
2 |
Anti-von willebrand factor nanobody, inn = caplacizumab |
Caplacizumab |
[1] D11160 D11160 💬 |
VWF [1] VWF 💬 |
Complement and coagulation cascades [8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation |
064 [1] 64 💬 |
3 |
Cablivi |
- |
- |
- |
- |
064 [1] 64 💬 |
4 |
Caplacizumab |
Caplacizumab |
[1] D11160 D11160 💬 |
VWF [1] VWF 💬 |
Complement and coagulation cascades [8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation |
064 [1] 64 💬 |
5 |
Caplacizumab (alx-0081) |
Caplacizumab |
[1] D11160 D11160 💬 |
VWF [1] VWF 💬 |
Complement and coagulation cascades [8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation |
064 [1] 64 💬 |
6 |
Caplacizumab (an anti-von willebrand factor nanobody alx-0081) |
Caplacizumab |
[1] D11160 D11160 💬 |
VWF [1] VWF 💬 |
Complement and coagulation cascades [8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation |
064 [1] 64 💬 |
7 |
Caplacizumab (an anti-von willebrand factor nanobody) |
Caplacizumab |
[1] D11160 D11160 💬 |
VWF [1] VWF 💬 |
Complement and coagulation cascades [8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation |
064 [1] 64 💬 |